Re:Search Institution Members

157 Results for Members


Former member - Now part of Pfizer Inc.

iThemba Pharmaceuticals ( is a company set up in South Africa with the specific aim of...

Kineta is a privately held emerging biotech company that was founded in 2008.

The Public Health Research Institute (PHRI) is a 76-year-old specialized center for global infectious diseases...

UF Innovate is a research institution, composed of four organizations, that actively contributes to research...

The Burnet Institute is an independent organization aiming to improve the health of vulnerable communities...

166 Results for Collaborations


Strengthening molecular surveillance and development of genomic tools that can be used in malaria control and elimination strategies in PNG, for example: Next Generation Sequencing; MinION portable sequencer. The fellowship of Dulcie Lautu from the Papua New Guinea Institute of Medical Research with the host scientist Alyssa Barry from the alter and Eliza Hall Institute of Medical Research (WEHI), Australia, aimed to enhance understanding of strategies (tools/approaches) for population genetics analysis.

The fellowship of Mohammad Shafiul Alam from the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) with the Griffith Institute for Drug Discovery (GRIDD), Australia and the host scientists Katherine Andrews and Vicky Avery provided opportunity to learn a range of drug discovery skills such as extraction and further purification of natural products, 3H-hypoxanthine uptake assays, cytotoxicity assay and phytochemical analysis. A total of 33 biota samples were obtained from the nature bank at GRIDD and screened for anti-plasmodial activity against reference strain of P. falciparum using a 72 hours isotopic micro test (3H-hypoxanthine uptake assays). After initial screening, 19 biota samples which had 50% inhibition in 10 mg/ml concentration were further investigated for selectivity index (cytotoxicity assay with Hek 293).

Malaria is a major public health threat in sub-Saharan Africa, and drug resistance is a major threat to current control efforts. Resistance to traditional antimalarials, including chloroquine and the antifolates, is widespread among the major causative parasite, Plasmodium falciparum. Artemisinin combination therapies, comprising an artemisinin derivative combined with a longer-acting partner drug such as lumefantrine or piperaquine, are the recommended treatment for falciparum malaria. However, resistance to the partner drugs is now widespread, and artemisinin resistance has recently spread throughout South-East Asia. Alarming reports of artemisinin resistance in sub-Saharan Africa are beginning to emerge, and improved methods to detect and monitor drug resistance in the field are urgently required.

The fellow Deus Ishengoma has an established research program monitoring antimalarial drug resistance in Tanzania, and aims to improve detection tools to allow routine monitoring in field settings. The host scientists Christian Doerig and Darren Creek at Monash University have developed advanced techniques for system-wide biochemical analysis of malaria parasites. These mass spectrometry and infrared (ATR-IR) spectroscopy approaches allow highly sensitive metabolomics and proteomics analyses, and may provide an alternative approach for detecting drug resistance phenotypes to established genetic tools such as mutation-dependent PCR tests.

Recent work from Darren Creek has revealed that the levels of a specific protein (Kelch13), haemoglobin-derived peptides and antioxidant molecules are associated with artemisinin-resistant parasites of South-East Asian origin (Siddiqui G, et al., J Infect Dis. In press). The collaboration wants to determine whether the abundance of these, or other specific molecules, is also associated with drug resistance in African parasites. The hypothesis that underlies this project is that metabolite and/or protein signatures of drug resistance will allow the development of point-of-care testing devices for antimalarial drug resistance.

Tedjo Sasmono from the Eijkman Institute for Molecular Biology, Indonesia, and his host scientists at the Walter and Eliza Hall Institute of Medical Research (WEHI), Australia, Diana Hansen and Alan Cowman, fixed as a primary R&D objective to establish inflammatory pathways and to identify effector cell populations and mechanisms associated with the development of severe Dengue. They used state-of-the-art technology including cytometry by time-of-flight (CyTOF) and next generation sequencing (NGS) to compare immunological pathways involved during disease progression in mild and severe Dengue. The CyTOF method combines the power of flow-cytometry with mass spectrometry. This tool enabled Tedjo Sasmono and hosts to identify the roles immune cells play in determining the severity of Dengue. The NGS methodology additionally helped researchers profile the role of various genes in the determining disease severity.

Malaria kills almost half a million people each year, mostly young children in sub-Saharan Africa. Decreased sensitivity of malaria parasite field isolates to artemisinin, the most recent antimalarial to be used in the field, is emerging, and it is of crucial importance to maintain an active research to develop new interventions. People living in malaria endemic areas develop naturally acquired immunity (NAI) after repeated exposure to malaria. However, the mechanism of NAI is not well understood. The fellowship aims to improve the understanding of how naturally acquired immunity works to protect against clinical malaria. For that purpose, the host scientists Darren Creek and Christian Doerig at Monash University, Australia, and the fellow Abdirahman Abdi from the Kenya Medical Research Institute have conducted controlled human malaria infection on Kenyan adults who had had varying levels of prior exposure to natural malaria infection.

Rintis Noviyanti from the Eijkman Institute for Molecular Biology (EIMB), Indonesia, and the host scientists at the Walter and Eliza Hall of Medical Research (WEHI), Australia, Diana Hansen and Alan Cowman, employed advanced technology and research methods, including cytometry by time-of-flight (CyTOF), and fluorescence-activated cell sorting (FACS), a derivative of flow cytometry that adds an exceptional degree of functionality for sorting cells. They used these technologies and methods, together with data mining and analysis, to identify biological markers present in individuals with natural immunity to Malaria.

170 Results for Assets


Malaria therapeutic Release of hemoglobin into the blood is a central pathophysiologic event contributing to morbidity and mortality in chronic and acute hemolytic anemias and severe malaria. These toxicities arise from hemoglobin-related scavenging of nitric oxide, a blood vessel vasodilator, and peroxidative chain reactions that lead to damage of the surrounding tissues. Animal models have demonstrated both an attenuation of the hypertensive response due to nitric oxide scavenging and a prevention of peroxidative toxicity. Compartmentalization of hemoglobin, rather than short-lived nitric oxide-based drugs, may represent a new therapeutic paradigm in countering the pathophysiological side effects associated with free hemoglobin. This technology identifies haptoglobin and haptoglobin mimetics as potential therapeutics for high blood pressure and intravascular toxicity due to release of hemoglobin from red blood cells. It provides a novel process in which free hemoglobin is compartmentalized within the haptoglobin molecule. Therapeutic proof-of-principle has been demonstrated for this technology in dog and guinea pig models.
This invention relates to the identification of functional domains of Plasmodium proteins which play a role in erythrocyte binding and invasion. The inventors have identified the erythrocyte binding domains of the sialic acid binding protein (SABP) of P. falciparum and the Duffy antigen binding protein (DABP) of P. vivax. The erythrocyte binding domains can be used as vaccines to induce immune responses which block erythrocyte binding and invasion by P. falciparum and P. vivax merozoites.
Anti-plasmodium composition and methods of use Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes are provided. More particularly, antibodies specific for Plasmodium falciparum binding proteins and blocking peptides that prevent the binding of Plasmodium falciparum are included in the present invention. The methods provided utilize the antibody and peptide compositions provided herein and include methods for the diagnosis, prevention, and treatment of Plasmodium falciparum diseases such as malaria as well as methods for the detection of Plasmodium falciparum in biological samples and culture media.
Compounds inhibiting the growth of a virulent strain (H37Rv) of Mycobacterium tuberculosis (Mtb) were discovered by testing 214,519 thousand pure, small molecules with drug like propertiesin a biosafety level 3 hiboratory. Discovery of novel pharmacophores inhibiting the growth of mycobacterium tuberculosis employed screening of a 214,519 pure, small molecules library that is part of the NIH Road Map Molecular Libraries Probe Centers Network MLSCN program. 610 compounds inhibited M tuberculosis growth by 90 per cent or greater and of these compounds, approximately 591 compounds were non-toxic to tissue culture cells at 10 J.lM. Twenty-two major chemical clusters covering approximately 243 active compounds were identified by structure similarity analysis along with 26 compounds in 6 minor clusters. Four hundred sixty-four active compounds did not form clusters. The potency ranged from <0.20 J.lM to I0 ~IM with 78 compounds having IC90s of>0.20 J.lM.
The present invention is related to a viral vaccine against rabies and use of the virus for producing rabiesvirus immunobiologicals. More particularly, the present invention is related to a genetically engineered plasmid vector that has been used to construct a unique vaccinia poxvirus infectious recombinant for expressing in animals or in tissue cultures part or all of the gene for rabiesvirus glycoprotein. Such a recombinant employing vaccinia or other poxviruses, could be used for production of rabies vaccine, live or inactivated, as well as for production of rabiesvirus glycoprotein antigen, antibody or other related biochemical or immunological reagents.
The invention relates to the design and synthesis of linear and cyclic inhibitors of cathepsin D and plasmepsins I and II. The present invention also relates to the uses of these inhibitors for inhibiting invasion and metastasis of cancerous cells. It also covers the use of cathepsin D and plasmepsin I and II inhibitors for the prevention and treatment of Alzheimer's disease and malaria. NIH Internal Reference no E-221-1994/0-US-01; US Patent Application no 08/603,737; E-221-1994/0-AU-03; AU Patent Application no 21368/97;E-221-1994/0-CA-04; CA Patent Application no 2246758; E-221-1994/0-EP-05; EP Patent Application no 97906763.4; E-221-1994/0-JP-06; JP Patent Application no 9-529609; The invention relates to the design and synthesis of linear and cyclic inhibitors of cathepsin D and plasmepsins I and II. The present invention also relates to the uses of these inhibitors for inhibiting invasion and metastasis of cancerous cells. It also covers the use of cathepsin D and plasmepsin I and II inhibitors for the prevention and treatment of Alzheimer's disease and malaria.